Clinical trials: Advanced Solid Tumors Patients
Solid Tumor
A Study of CBP-1018 in Patients With Advanced Solid Tumors
This is an open-label, non-randomized, multi-center, phase I study of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.
- Trial name
- NCT04928612
- Testing
- CBP-1018
- Where
- 2 sites in China
- Volunteers
- 170 people
- Sponsor
- Coherent Biopharma (Suzhou) Co., Ltd.
Cancer, Neoplasm Metastasis
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
- Trial name
- NCT00492830
- Testing
- TRC093 recombinant humanized IgG1k monoclonal antibody
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Tracon Pharmaceuticals Inc.
RAS Mutation, NF1 Mutation
PAS-004 in Patients With Advanced Solid Tumors
The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations.
- Conditions
- RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
- Trial name
- NCT06299839
- Testing
- PAS-004 Capsules, PAS-004 Tablets
- Where
- 5 sites in United States, Bulgaria and 1 more
- Volunteers
- 83 people
- Sponsor
- Pasithea Therapeutics Corp.
Advanced Solid Tumors
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and to determine the maximum tolerable dose (MTD) and/or recommended phase 2 dose (RP2D) of HH30134 administered orally on a continuous…
- Trial name
- NCT04746612
- Testing
- HH30134
- Where
- 4 sites in Australia, China
- Volunteers
- 22 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma…
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03682289
- Testing
- Ceralasertib, Olaparib, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Rahul Aggarwal
Advanced Solid Tumour
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
- Trial name
- NCT07331155
- Testing
- LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumor, Metastatic Cancer
FIH XON7 in Advanced/Metastatic Solid Tumors
This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to…
- Trial name
- FIPO23 (NCT06154291)
- Testing
- XON7
- Where
- 5 sites in Belgium, France
- Volunteers
- 255 people
- Sponsor
- Xenothera SAS
Unspecified Adult Solid Tumor, Protocol Specific
Green Tea Extract in Treating Patients With Advanced Solid Tumors
RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers, as well as prevent the development of new cancers.
- Trial name
- NCT00003197
- Testing
- green tea extract
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
This phase III trial compares olanzapine to placebo in decreasing nausea and vomiting in patients with cancer that has spread to other places in the body (advanced).
- Trial name
- NCT05403580
- Testing
- Olanzapine, Questionnaire Administration
- Sponsor
- Mayo Clinic
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of sirolimus and gold sodium thiomalate when given together in treating patients with advanced squamous non-small cell lung cancer (NSCLC).
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT01383668
- Testing
- sirolimus, gold sodium thiomalate, pharmacological study
- Sponsor
- Mayo Clinic
Solid Tumor, Ovarian Cancer
LDE225 and Paclitaxel in Solid Tumors
The primary aim of this trial is to establish the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of LDE225 given in combination with standard doses of paclitaxel in patients with advanced solid tumors.
- Trial name
- NCT01954355
- Testing
- LDE225, Paclitaxel
- Where
- 4 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Swiss Cancer Institute
Tumor, Solid, Lymphoma
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
This is a Phase I clinical study for evaluating the safety, pharmacokinetics, and preliminary efficacy of repeated doses, dose escalation of GR1405 injection in patients with advanced solid tumor or lymphoma
- Trial name
- NCT03731390
- Testing
- GR1405 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
This phase I study will determine the pharmacokinetic profile of patupilone in patients with mild or moderately impaired hepatic function within 2 cycles of treatment.
- Trial name
- NCT00420524
- Testing
- Patupilone/EPO906
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
A Study of SHR-1802 in Patients With Advanced Solid Tumor
To assess the safety and tolerability of SHR-1802 combined with camrelizumab and famitinib in subjects with advanced solid tumor and to determine the dose-limiting toxicity (DLT)，recommended phase II dose (RP2D) and assess…
- Trial name
- NCT05208177
- Testing
- SHR-1802＋camrelizumab + famitinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in treating patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT00119236
- Testing
- tanespimycin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Tumors
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced…
- Trial name
- NCT00395434
- Testing
- Combretastatin A4 Phosphate (CA4P), Bevacizumab (Avastin)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Mateon Therapeutics
Solid Tumor, Melanoma
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Melanoma, HNSCC, Sarcoma
- Trial name
- NCT04370587
- Testing
- T3011, T3011 + pembrolizumab
- Where
- 9 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- ImmVira Pharma Co. Ltd
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
This phase II MATCH treatment trial identifies the effects of nivolumab in patients whose cancer has a genetic change called mismatch repair deficiency.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439214
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
This is a phase I, open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of PAN-NeoVax, an artificial intelligence (AI)-designed pan-cancer…
- Trial name
- NCT07560943
- Testing
- PAN-NeoVax (25 μg), PAN-NeoVax (50 μg), PAN-NeoVax (100 μg)
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Advanced Cancers
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.
- Trial name
- NCT02042989
- Testing
- MLN9708, Vorinostat
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.